Form 4: Cue Biopharma Director Receives Stock Option Grant

Cue Biopharma Director Peter A Kiener was granted 24,400 stock options as part of the company's compensation policy.

Summary

• Peter A Kiener, a Director at Cue Biopharma, Inc. (CUE), was granted 24,400 stock options.
• The stock options have an exercise price of $0.34 per share.
• The grant date for these options was January 2, 2026.
• The options will become fully exercisable on the first anniversary of the grant date, which is January 2, 2027.
• The expiration date for these stock options is January 1, 2036.
• This award was made pursuant to the Issuer's Director Compensation Policy.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally neutral to slightly positive as it aligns interests without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• It represents a standard component of director compensation, indicating adherence to established corporate governance practices.

Negatives

• The exercise of these options in the future could lead to minor dilution for existing shareholders, although the amount is relatively small.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting and expiration dates of the granted options.

Industry Context

The grant of stock options to directors is a common practice across the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in the biopharmaceutical industry, comparable to compensation structures seen in companies like Moderna or BioNTech, which frequently use equity-based incentives.
• The vesting schedule, with options becoming fully exercisable on the first anniversary, is a typical approach to encourage continued service and long-term commitment.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Peter A Kiener): Receives equity-based compensation, increasing his stake and potential future wealth tied to company performance.

Next Steps

• The stock options will become fully exercisable on January 2, 2027, at which point the director may choose to exercise them.

Key Dates

Keywords

Cue Biopharma, CUE, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Biopharma